1. Qi-Tang Huang#, Quan-Quan Hu#, Zhao-Feng Wen, Yan-Li Li*. Iron oxide nanoparticles inhibit tumor growth by ferroptosis in diffuse large B-cell lymphoma. Am J Cancer Res 2023;13(2):498-508. (IF=5.942, Q2, 中科院二区)
2. Quan-Quan Hu#, Zhao-Feng Wen#, Qi-Tang Huang, Qian Li, Zhi-Min Zhai, Yan-Li Li*. CC chemokine receptor 2 (CCR2) expression promotes diffuse large B-Cell lymphoma survival and invasion. Lab Invest 2022;102(12):1377- 1388. (Nature Publishing Group, USCAP期刊, IF=5.502, Q1, 中科院二区)
3. Yan‐Li Li, Hui‐Ping Wang, Cui Zhang, Zhi‐Min Zhai. CD20-positive primary nasal peripheral T-cell lymphoma: An analysis of one case and review of the literature. Cytometry B Clin Cytom 2020;98(4):348-354. (IF=3.248, Q2)
4. Yan-Li Li, Zhi-Hu Shi, Xian Wang, Kang-Sheng Gu, Zhi-Min Zhai. Tumor- associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count. BMC Cancer 2019; 19(1):1049. (IF=3.333, Q2)
5. Yan-Li Li, Zhi-Hu Shi, Xian Wang, Kang-Sheng Gu, Zhi-Min Zhai. Prognostic significance of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in diffuse large B cell lymphoma. Ann Hematol 2019;98 (2):413-422. (IF=2.85, Q2)
6. Li YL, Gu KS, Pan YY, Jiao Y, Zhai ZM. Peripheral blood lymphocyte/ monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. BMC Cancer 2014;14:341.
7. Li YL, Pan YY, Jiao Y, Ning J, Fan YG, Zhai ZM. Peripheral blood lymphocyte/ monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens. Ann Hematol 2014;93(4):617- 626.
8. Yan-Li L, Kang-Sheng G, Yue-Yin P, Yang J, Zhi-Min Z. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leuk Res 2014;38(3):323-328.
9. Cai L, Li YL, Hu XY, Li R Implementation of flipped classroom combined with case-based learning: A promising and effective teaching modality in undergraduate pathology education. Medicine (Baltimore) 2022;101(5): e28782.
10. He-Qin Zhan, Rong Qin, Yan-Li Li, Meng-Meng Liu, Lin Gan. TFEB promotes BCL-2 expression by upregulating its promoter activity in the t(6;11) translocation renal cell carcinomas. Am J Transl Res 2021;13(8):8804-8818.
11. He-Qin Zhan, Shu-Ting Li, Yan Shu, Meng-Meng Liu, Rong Qin, Yan-Li Li, Lin Gan. Alpha gene upregulates TFEB expression in renal cell carcinoma with t(6;11) translocation, which promotes cell canceration. Int J Oncol 2018;52(3): 933-944.
12. Zhi-Tao Wang, Lulu Zhang, Huiping Wang, Shudao Xiong, Yanli Li, Qianshan Tao, Weihua Xiao, Hui Qin, Yiping Wang, Zhimin Zhai. Tumor- induced CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients. Cancer Immunol Immunother 2015;64(3):389-399.
13. Yang Jiao, Jie Ning, Wen-Di Zhao, Yan-Li Li, Hong-Yang Wu, Kang-Sheng Gu. Sarcoidosis in gastric cancer at the time of diagnosis: A case report. Oncol Lett 2015;9(3):1159-1162.
14. 闻照凤，黄绮堂，胡泉泉，李雨，李延莉*。NOD-Scid小鼠播散性弥漫大B细胞淋巴瘤模型的构建。《临床与实验病理学杂志》2023;39(7):793-796。
15. 闻照凤，胡泉泉，黄绮堂，李雨，朱俊，王弦，李延莉*。STAT3在弥漫大B细胞淋巴瘤中表达及与临床预后和肿瘤相关巨噬细胞的关系。《临床与实验病理学杂志》2023;39(2):157-161。
16. 闻照凤，李延莉*。铁蛋白自噬在癌症发生发展中作用的研究进展。《中国病理生理杂志》2022;38(7):1340-1344。
17. 黄绮堂，李延莉*。铁代谢异常与淋巴造血系统肿瘤的研究进展。《中国实验血液学杂志》2022;30(4):1277-1280。
18. 胡泉泉，王会平，顾康生，翟志敏，李延莉*。外周血中间型单核细胞增多与弥漫大B细胞淋巴瘤疾病进展的相关性研究。《中国实验血液学杂志》2022;30(4):1116- 1122。
19. 史梦雯，刘玲玲，刘啸，张雪虎，李延莉*。重症监护病房医护人员总体幸福感影响因素及与自测健康的相关性分析。《安徽医学》2020;41(3):350-353。
20. 李延莉*。自学能力导向的病理学点拨教学法探讨。《现代医药卫生》2019;35 (12):1875-1877。
21. 李延莉，翟志敏。表观遗传学在淋巴系统肿瘤研究中的新进展。《中国实验血液学杂志》2012;20(1):219-223。
